Pfizer’s share price has languished at multiyear lows after three consecutive years of underperformance driven by patent expirations and uneven revenue growth. The company’s market capitalization stands at approximately $142 billion, with gross margins near 69 percent. At a forward earnings multiple of 8.5 times, Pfizer trades at roughly half the valuation of the broader healthcare sector, while its average daily trading volume has fallen by nearly 80 percent compared with peak levels during the pandemic.

While Pfizer faces major patent expirations—most notably for its blockbuster anticoagulant Eliquis—its R&D engine is showing signs of life. Since 2023 the company has secured multiple regulatory approvals spanning oncology and rare diseases, and it now fields over thirty late-stage candidates, including a promising weight-management therapy and next-generation cancer immunotherapies. Management projects that these launches, combined with forthcoming label expansions, will drive mid‐single‐digit revenue growth through 2030, helping to offset sales erosion from expiring exclusivities.

In preparation for cost pressures, Pfizer has announced price adjustments on roughly eighty branded therapies beginning in 2026, with most hikes capped below 10 percent and select hospital injectables seeing steeper increases. The company also secured a three-year tariff exemption agreement with the U.S. government to mitigate inflationary headwinds. On the income front, Pfizer has raised its dividend by over 50 percent during the last decade, delivering a forward yield near 7 percent, and has supplemented its pipeline through strategic acquisitions totalling more than $30 billion since 2022.